This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
3808 |
4. Check minimum number of events
Min. number of events
3
|
3808 |
5. Include endpointsNone |
3808 |
6. Filter based on genotype QC (FinnGen only) |
3688 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- First used in FinnGen datafreeze
- DF3
Similar endpoints
↥List of similar endpoints to
L02BB Anti-androgens
based on the number of shared cases.
Similar with more cases:
- Malignant neoplasm, wide definition for exclusion
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 3688 | - | 3686 |
| Unadjusted period prevalence (%) | 1.69 | - | 1.69 |
| Median age at first event (years) | 72.22 | - | 72.23 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 3808
- Matched controls
- 38080
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
ZX112
NOMESCO Finland
Subcutaneous
11.5
321.5
345
326
L02BB01
ATC
flutamide; oral
57.2
319.6
180
33
A03FA01
ATC
metoclopramide; systemic, rectal
4.3
307.7
1343
4285
XX3DW
NOMESCO Finland
Time consuming IT work
4.6
307.7
942
2528
L02BX03
ATC
abiraterone; oral
118.6
307.7
722
75
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
9.5
307.7
596
732
116
Kela drug reimbursment
Prostate cancer
1111.2
307.7
3761
2558
L02AE03
ATC
goserelin; implant
26.4
307.7
447
191
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
163.3
307.7
3650
4719
163
Kela drug reimbursment
Abiraterone and enzalutamide
216.2
307.7
1139
75
L02AE02
ATC
leuprorelin; implant, parenteral
29.9
307.7
2290
1829
L02AE04
ATC
triptorelin; parenteral
13.0
307.7
370
312
ZX090
NOMESCO Finland
Other technic of radiotherapy
10.0
307.7
390
430
H02AB02
ATC
dexamethasone; systemic
7.3
307.7
1131
2087
L02BB04
ATC
enzalutamide; oral
861.6
307.7
1266
22
L02BB03
ATC
bicalutamide; oral
305.6
307.7
3088
527
R74.8
ICD-10 Finland
Abnormal levels of other serum enzymes
5.9
307.7
1067
2366
WD205
NOMESCO Finland
Therapy of methastized malignancy with hormones
83.3
307.7
403
54
WD225
NOMESCO Finland
Demanding therapy of methastized malignancy with hormones
41.1
307.7
415
113
TKE00
NOMESCO Finland
Needle biopsy of prostate
5.7
307.7
908
1977
G03HA01
ATC
cyproterone; systemic
17.1
307.7
295
186
WF049
NOMESCO Finland
Radiotherapy of metastasis
14.0
307.7
804
715
C79.5
ICD-10 Finland
Secondary malignant neoplasm of bone and bone marrow
31.9
307.7
865
348
352
Kela drug reimbursment
Abiraterone and enzalutamide
149.8
307.7
786
66
ZX013
NOMESCO Finland
Radiotherapy with large shaped fields - SSD therapy
59.7
307.7
277
50
XKD00
NOMESCO Finland
Uroflowmetry
3.8
307.7
2026
8725
1523, ,
Kela drug reimbursment
729.6
307.7
663
11
Y77
ICPC
Malignant neoplasm prostate
22.0
307.7
1526
1123
C61
ICD-10 Finland
Malignant neoplasm of prostate
939.8
307.7
3782
5104
JN4BD
NOMESCO Finland
Extensive body CT
4.6
307.7
1025
2844
L03AA13
ATC
pegfilgrastim; parenteral
12.2
307.7
440
402
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
12.9
307.7
760
721
WF090
NOMESCO Finland
Profylactic radiotherapy
205.0
307.7
560
32
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
7.9
307.7
684
1030
3054, ,
Kela drug reimbursment
726.9
307.7
661
11
M05BX04
ATC
denosumab; parenteral
22.4
307.7
1013
607
KE1AT
NOMESCO Finland
Biopsy of prostata with ultrasoudnguidance
7.4
307.7
1390
2731
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
6.1
307.7
2168
6789
YL1BD
NOMESCO Finland
Extensive CT examination of pelvis for dose design of radiotherapy
9.6
307.7
501
590
L02BX02
ATC
degarelix; parenteral
30.5
307.7
685
272
NK6AN
NOMESCO Finland
Total body bone isotope imaging
13.2
307.7
659
594
Z51.5
ICD-10 Finland
Palliative care
4.5
306.3
916
2511
N02AA05
ATC
oxycodone; systemic
3.6
304.2
1471
5637
WF002
NOMESCO Finland
Radical radiotherapy
4.9
296.0
766
1869
308
Kela drug reimbursment
Alprostadil, sildenafil and combination product containing aviptadil and phentolamine
8.1
290.2
411
558
L01XX11
ATC
estramustine; systemic
46.6
280.8
165
37
WD305
NOMESCO Finland
Simple therapy of methastized malignancy with biomodifiers
15.1
257.7
231
162
WZC00
NOMESCO Finland
Treatment plan or consultation
3.1
255.8
1763
8198
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
3.2
254.1
1561
6788
YL1AD
NOMESCO Finland
CT examination of pelvis for dose design of radiotherapy
7.4
216.5
330
484
KEC01
NOMESCO Finland
Percutaneous endoscopic radical prostatectomy
6.6
216.3
369
610
WF004
NOMESCO Finland
Palliative radiotherapy
7.4
214.7
327
479
L03AA14
ATC
lipegfilgrastim; parenteral
17.5
214.1
177
106
XX9AN
NOMESCO Finland
Complementary isotope examination or additional picture
58.5
212.3
119
21
PJD64
NOMESCO Finland
Laparoscopic dissection of iliac lymph nodes
10.8
210.9
233
228
1CD02, ,
NOMESCO Finland
65.8
209.4
115
18
KEC00
NOMESCO Finland
Retropubic radical prostatectomy
7.0
206.0
329
507
XJH00
NOMESCO Finland
Transanal ultrasonography
3.4
204.1
907
3192
WVA30, ,
SPAT
5.2
198.9
449
963
JN4AD
NOMESCO Finland
Body CT examination
3.4
192.4
824
2824
WD215
NOMESCO Finland
Multiple therapy of methastized malignancy with hormones
51.5
191.4
110
22
C77.8
ICD-10 Finland
Secondary and unspecified malignant neoplasm: Lymph nodes of multiple regions
23.4
180.9
131
58
KFC10
NOMESCO Finland
Bilateral orchiectomy
14.3
180.7
166
121
KE1DR
NOMESCO Finland
Prostate metabolic PET with CT
29.7
177.7
118
41
C77.5
ICD-10 Finland
Secondary and unspecified malignant neoplasm: Intrapelvic lymph nodes
33.2
176.3
113
35
G04BE03
ATC
sildenafil; oral
7.1
174.6
271
404
L02BB05
ATC
apalutamide; oral
576.3
168.5
166
*
2BX02, ,
NOMESCO Finland
57.6
160.0
90
16
3031
Kela drug reimbursment
Apalutamidi
275.2
155.7
158
6
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
4.2
155.3
461
1222
1528, ,
Kela drug reimbursment
273.3
154.6
157
6
A04AA01
ATC
ondansetron; systemic, rectal
4.1
152.9
465
1254
C77.2
ICD-10 Finland
Secondary and unspecified malignant neoplasm: Intra-abdominal lymph nodes
17.2
147.3
122
73
ZX080
NOMESCO Finland
Image guided radiotherapy
8.3
147.2
198
250
A04AA02
ATC
granisetron; systemic, transdermal
4.2
144.4
415
1072
J01EA01
ATC
trimethoprim; systemic
2.7
141.9
943
4079
KE3AT
NOMESCO Finland
Transrectal gold marker implantation in prostate under ultrasound guidance
4.7
141.6
350
804
XX7FT
NOMESCO Finland
Radioyttrium therapy with connected antibody
249.3
141.1
144
6
R86.0
ICD-10 Finland
Abnormal findings in specimens from male genital organs, abnormal level of enzymes
4.6
140.7
355
829
N13.3
ICD-10 Finland
Other and unspecified hydronephrosis
5.8
139.6
265
483
YX9AD
NOMESCO Finland
Other CT eamination for dose design of radiotherapy
6.0
139.4
254
445
YJ2VG
NOMESCO Finland
MRI examination of pelvis with high intensity magnet for dose design of radiotherapy
6.2
137.6
243
413
JN4LR
NOMESCO Finland
Extensive PET-CT of receptors in whole body
41.9
136.2
82
20
YN7AD
NOMESCO Finland
CT examination of spine for dose design of radiotherapy
23.4
135.6
98
43
A79
ICPC
Malignancy NOS
7.8
134.5
190
254
KE002
NOMESCO Finland
Radical radiotherapy of prostata and seminal vesicles
15.8
129.4
112
73
NK6BQ
NOMESCO Finland
Whole body extensive bone SPET with low dose CT
12.3
129.0
129
108
J01MA02
ATC
ciprofloxacin; systemic
2.2
124.3
2008
12724
ZXC96
NOMESCO Finland
Robot assisted procedure
5.1
121.6
269
562
M87.1
ICD-10 Finland
Osteonecrosis due to drugs
22.2
120.7
89
41
HB000
NOMESCO Finland
Profylactic radiotherapy of mammary gland
254.1
120.7
123
5
D40.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Prostate
4.9
119.5
274
590
KH1BT
NOMESCO Finland
Urinary tract cathetrisation with X-ray guidance
7.7
118.6
170
231
XX1XQ
NOMESCO Finland
Other SPECT-CT
208.2
117.3
121
6
UKC02
NOMESCO Finland
Cystoscopy
2.3
116.3
1333
7303
YN7BD
NOMESCO Finland
Extensive CT examination of spine for dose design of radiotherapy
19.6
115.7
90
47
WF003
NOMESCO Finland
Adjuvant radiotherapy
5.3
115.0
240
476
WF099
NOMESCO Finland
Other radiotherapy
15.5
111.2
97
64
Z03.1
ICD-10 Finland
Observation for suspected malignant neoplasm
4.9
111.1
256
553
U77
ICPC
Malignant neopl urinary tract other
20.2
110.8
85
43
Z51.0
ICD-10 Finland
Radiotherapy session
7.5
109.1
159
220
ZX070
NOMESCO Finland
Intensity modified radiotherapy
5.4
104.9
216
423
5BX04, ,
NOMESCO Finland
46.1
100.1
59
13
Y06
ICPC
Prostate symptom/complaint
3.3
96.2
394
1283
NK6AQ
NOMESCO Finland
Whole body bone SPET with low dose CT
15.3
95.7
84
56
KH1FT
NOMESCO Finland
Exchange of urinary catheter with radiological guidance
11.1
95.7
102
94
WF029
NOMESCO Finland
Radiotherapy of local residive tumor
9.9
95.1
110
114
A06AH03
ATC
naloxegol; oral
6.9
94.3
149
225
K62.7
ICD-10 Finland
Radiation proctitis
7.7
94.3
133
177
JN5ER
NOMESCO Finland
PET-CT of receptors in whole body
10.9
93.5
101
95
SPAT1256
SPAT
Intramuscular and subcutaneous injection
2.0
93.2
1799
11760
R31
ICD-10 Finland
Unspecified haematuria
2.2
84.1
881
4559
ZX120
NOMESCO Finland
Intravenous
2.6
80.8
516
2139
1850A
ICD-9 Finland
Malignant neoplasm of prostate[NEOPLASMA MALIGNUM PROSTATAE]
10.7
79.7
87
83
PJD44
NOMESCO Finland
Excision of iliac lymph nodes
8.1
76.7
104
132
R33
ICD-10 Finland
Retention of urine
2.2
76.1
784
4011
KEB00
NOMESCO Finland
Biopsy of prostate
4.3
74.4
196
470
KE1BE
NOMESCO Finland
Rectal ultrasound examinaiton of prostata
2.1
72.9
859
4622
WW500
NOMESCO Finland
Blood transfusion
3.4
72.6
278
865
L02BB06
ATC
darolutamide; oral
721.8
72.4
71
*
TKE10
NOMESCO Finland
Puncture of prostate
6.2
70.7
123
205
OAB42
NOMESCO Finland
Guidance related to known health problem
11.1
69.5
74
68
G04BE01
ATC
alprostadil; parenteral, urethral
3.4
69.2
257
784
XX7LT
NOMESCO Finland
Lutetium-177-PSMA treatment
237.6
68.5
70
*
WZC30
NOMESCO Finland
Teaching
2.2
67.2
721
3730
KC1GB
NOMESCO Finland
Cystography with X-ray
5.5
65.5
129
242
XX7AT
NOMESCO Finland
Radiation therapy with Radium-223
322.4
63.6
64
*
Z08.1
ICD-10 Finland
Follow-up examination after radiotherapy for malignant neoplasm
10.3
60.0
67
66
TKC10
NOMESCO Finland
Percutaneous puncture of bladder
3.9
59.4
178
469
ZX020
NOMESCO Finland
HDR radiotherapy within tissue
14.5
58.8
53
37
G04CA02
ATC
tamsulosin; oral
1.7
57.5
2107
15908
N42.9
ICD-10 Finland
Disorder of prostate, unspecified
3.8
57.5
180
489
Z08.7
ICD-10 Finland
Follow-up examination after combined treatment for malignant neoplasm
8.7
56.0
71
83
ZXC20
NOMESCO Finland
Use of chemical agents
3.8
55.7
175
477
ZX050
NOMESCO Finland
Stereotactic radiotherapy
6.3
54.4
92
149
KBV15
NOMESCO Finland
Cystoscopic change of ureteral stent
8.1
52.9
71
89
Z3231
NOMESCO Finland
Registered nurse
1.8
52.8
1169
7625
JN2CG
NOMESCO Finland
Extensive MRI examination of lower part of abdoment with high intensity magnet
4.9
52.7
117
244
XX7JT
NOMESCO Finland
Somatostatin isotope ablative therapy
22.6
51.8
38
17
7512
FHL
Orchidectomy (bilateral)
14.8
49.4
44
30
TKC20
NOMESCO Finland
Catheterisation of bladder
2.2
49.3
489
2433
ZX112, ,
SPAT
12.1
48.8
49
41
3036, ,
Kela drug reimbursment
483.9
48.5
48
*
1525, ,
Kela drug reimbursment
483.9
48.5
48
*
TKC22
NOMESCO Finland
Catheterisation instruction
3.1
48.3
206
682
K52.0
ICD-10 Finland
Gastroenteritis and colitis due to radiation
9.1
48.1
59
66
KDV12
NOMESCO Finland
Urethroscopic internal urethrotomy
4.0
47.4
135
343
KH1YT
NOMESCO Finland
Percutaneous implantation of endoprothesis with radiological guidance
8.9
45.8
57
65
N02BE01
ATC
paracetamol; systemic, rectal
1.9
45.7
3144
27311
A49.9
ICD-10 Finland
Bacterial infection, unspecified
1.9
45.5
674
3863
5BA08, ,
NOMESCO Finland
10.3
44.0
49
48
XX1AD
NOMESCO Finland
Other CT-examination
7.3
43.6
64
89
A55
ICPC
General and Unspecified, Local injection/infiltration
6.4
43.2
72
115
G04BD12
ATC
mirabegron; oral
2.0
42.2
564
3117
XX3AT
NOMESCO Finland
Other labeling with ultrasound guidance
7.2
39.8
59
83
YG1BD
NOMESCO Finland
Extensive CT examination of thorax for dose design of radiotherapy
4.4
39.3
98
225
WB203
NOMESCO Finland
Simple adjuvant hormone therapy of malignancy
10.9
39.1
42
39
KA3EB
NOMESCO Finland
Antegrade pyelography
6.3
38.9
65
104
YX9BD
NOMESCO Finland
Other extensive CT eamination for dose design of radiotherapy
6.1
38.4
67
112
NK6SN
NOMESCO Finland
Bone SPECT
14.1
38.2
35
25
N39.3
ICD-10 Finland
Stress incontinence
4.3
37.7
97
228
1CD04, ,
NOMESCO Finland
371.0
37.1
37
*
Y50
ICPC
Male Genital, Medication/prescr/renewal
10.9
36.4
39
36
WVA30
NOMESCO Finland
Intramuscular and subcutaneous injection
8.3
36.0
47
57
A07EA02
ATC
hydrocortisone; rectal
3.7
35.3
115
321
JN2DM
NOMESCO Finland
Lower part of abdomen very extensive MRI examination with Tesla magnet
10.7
34.9
38
36
KBV02
NOMESCO Finland
Cystoscopic insertion of stent into ureter
3.1
34.6
149
496
A02BC02
ATC
pantoprazole; systemic
1.5
33.9
2383
19858
TQX05
NOMESCO Finland
Skin puncture, unspecified location
11.8
33.4
34
29
TNX00
NOMESCO Finland
Puncture and needle biopsy of soft tissue, unspecified region
4.4
31.8
79
181
G04BD08
ATC
solifenacin; oral
2.1
31.7
314
1551
M49.5*C79.5
ICD-10 Finland
Metastatic fracture of vertebra
11.9
31.6
32
27
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
5.1
31.3
65
128
N02AX02
ATC
tramadol; systemic, rectal
1.5
30.4
1617
12608
Y78
ICPC
Malign neopl male genital other
11.2
29.3
31
28
SPAT1088
SPAT
Blood transfusion
5.2
29.1
59
114
L03AA02
ATC
filgrastim; parenteral
3.0
28.9
131
449
H02AB06
ATC
prednisolone; systemic
1.5
28.6
1733
13807
166
Kela drug reimbursment
Dalteparin and tinzaparin (treatment for more than 6 months)
4.9
28.1
61
125
KED22
NOMESCO Finland
Transurethral resection of prostate
1.7
27.8
558
3463
SPAT1254
SPAT
Administration of medicine
1.7
27.6
628
4030
-50
ICPC
Medication/prescr/renewal
2.4
27.2
199
867
WVA20, ,
SPAT
3.2
26.7
109
352
TKW99
NOMESCO Finland
Other minor surgical procedure in urology
3.8
26.5
81
217
KD1GB
NOMESCO Finland
Uretrocystogpaphy with X-ray
7.4
26.3
38
52
N30.4
ICD-10 Finland
Irradiation cystitis
8.4
26.1
34
41
WB223
NOMESCO Finland
Demanding adjuvant hormone therapy of malignancy
5.6
25.8
49
89
KCW02
NOMESCO Finland
Lavation of bladder for coagulated blood
3.0
25.8
114
386
A06AD11
ATC
lactulose; oral
1.6
25.7
751
5116
A28
ICPC
Limited function/disability NOS
1.6
25.6
831
5795
TKC52
NOMESCO Finland
Patient education concerning pelvic floor contraction exercises
8.5
24.9
32
38
G04BE30
ATC
drugs used in erectile dysfunction - combinations
6.4
24.8
41
65
L02AE01
ATC
buserelin; implant, nasal, parenteral
21.4
24.7
36
17
WPA10
NOMESCO Finland
Proactive palliative care treatment plan
4.9
24.3
53
109
EB1BI
NOMESCO Finland
Cone beam imaging of teeth and jaws (1–2 quarters)
4.0
24.1
68
172
KE003
NOMESCO Finland
Adjuvant radiotherapy of prostata and seminal vesicles
29.3
24.1
32
11
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
2.1
24.0
221
1061
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
1.7
23.8
507
3187
Z08.8
ICD-10 Finland
Follow-up examination after other treatment for malignant neoplasm
6.6
23.8
38
58
G04CA52
ATC
tamsulosin and dutasteride; systemic
0.6
23.8
379
6201
WC205
NOMESCO Finland
Simple therapy of local tumor recidive with hormone
241.5
23.7
24
*
D70.82
ICD-10 Finland
Drug-induced neutropenia
3.9
23.6
69
179
B03XA02
ATC
darbepoetin alfa; parenteral
2.7
23.2
129
494
KA1AE
NOMESCO Finland
Kidney ultrasound examination
2.5
22.7
144
588
R50.9
ICD-10 Finland
Fever, unspecified
1.6
22.4
595
3950
WX408
NOMESCO Finland
General anesthesy, balanced
1.5
22.4
912
6651
U04
ICPC
Incontinence urine
2.1
22.1
220
1088
M84.4
ICD-10 Finland
Pathological fracture, not elsewhere classified
9.1
22.1
27
30
KH1AT
NOMESCO Finland
Urinary tract cathetrisation with ultrasound guidance
5.5
21.9
42
77
J01MA12
ATC
levofloxacin; systemic
1.5
21.9
833
5984
TPH04
NOMESCO Finland
Cathetrisation of vein
1.5
21.9
847
6109
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
1.8
21.8
355
2068
G04BE08
ATC
tadalafil; oral
6.9
21.6
33
48
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
1.6
21.1
572
3814
B01AB05
ATC
enoxaparin; parenteral
1.4
21.0
1121
8589
H02AB07
ATC
prednisone; oral
1.6
20.6
503
3267
J01DB01
ATC
cefalexin; oral
1.4
20.6
2714
24192
N35.9
ICD-10 Finland
Urethral stricture, unspecified
2.8
20.6
105
385
A50
ICPC
General and Unspecified, Medication/prescr/renewal
2.4
20.4
148
643
SPAT1154
SPAT
Insertion or removal of subcutaneous medicine capsule
7.8
20.4
28
36
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
2.1
20.3
189
910
-55
ICPC
Local injection/infiltration
4.6
20.3
48
106
D63.0
ICD-10 Finland
Anaemia in neoplastic disease
27.2
20.0
27
10
Z12.5
ICD-10 Finland
Special screening examination for neoplasm of prostate
3.0
19.6
89
306
KDK10
NOMESCO Finland
Implantation of artificial urinary sphincter around bulbar urethra
7.2
19.1
28
39
B01AB10
ATC
tinzaparin; parenteral
1.7
18.8
333
1988
8000/3-C61.9
ICD-O-3
Neoplasm, malignant of prostate gland
7.3
18.6
27
37
XX9AQ
NOMESCO Finland
Supplementary SPECT-CT or additional scan
14.2
18.5
31
22
R74.9
ICD-10 Finland
Abnormal level of unspecified serum enzyme
4.0
18.1
50
125
KCV22
NOMESCO Finland
Transluminal endoscopic evacuation of blood clots from bladder
5.7
18.0
33
58
N02AA03
ATC
hydromorphone; systemic, rectal
6.7
17.8
28
42
130
Kela drug reimbursment
Malignant tumour
0.5
17.8
161
3148
JN2BG
NOMESCO Finland
MRI examination of lower part of abdoment with high intensity magnet
6.2
17.6
30
49
N02AJ06
ATC
codeine and paracetamol; systemic
1.4
17.6
1164
9196
K62.8
ICD-10 Finland
Other specified diseases of anus and rectum
4.1
17.5
48
119
XKG00
NOMESCO Finland
Artificial induction of erection
6.2
17.2
29
47
XKW99
NOMESCO Finland
Other physiological examination of urinary or male genital system
2.6
17.2
101
399
KE099
NOMESCO Finland
Other radiotherapy of prostata and seminal vesicles
17.4
16.9
26
15
SPAT1109
SPAT
Analgesia with portable analgesic pump
4.0
16.9
47
118
U08
ICPC
Urinary retention
2.1
16.6
156
755
C77.9
ICD-10 Finland
Secondary and unspecified malignant neoplasm: Lymph node, unspecified
12.7
16.6
29
23
UKD02
NOMESCO Finland
Urethroscopy
4.1
16.6
45
111
KDG43
NOMESCO Finland
Transobturatorial sling urethrocystopexy
7.0
16.5
25
36
KE1BG
NOMESCO Finland
MRI of prostate
3.1
16.4
69
228
N47
ICD-10 Finland
Redundant prepuce, phimosis and paraphimosis
2.0
16.3
192
1008
S50
ICPC
Skin, Medication/prescr/renewal
4.0
16.2
45
113
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
1.4
16.1
1141
9086
L02AA02
ATC
polyestradiol phosphate; parenteral
30.2
16.1
21
7
R86.9
ICD-10 Finland
Abnormal findings in specimens from male genital organs, unspecified abnormal finding
3.5
15.9
53
151
M05BA08
ATC
zoledronic acid; parenteral
33.5
15.7
20
6
SPAT1167
SPAT
Insertion of urinary catheter
1.9
15.7
204
1108
G04BD11
ATC
fesoterodine; oral
2.3
15.6
122
548
M01AE01
ATC
ibuprofen; systemic, rectal
1.4
15.6
2685
24302
JN2CM
NOMESCO Finland
Lower part of abdomen extensive MRI examination with Tesla magnet
4.1
15.6
42
103
D64.9
ICD-10 Finland
Anaemia, unspecified
1.5
15.2
541
3808
ZXE20
NOMESCO Finland
More than three and less than five hours
1.5
15.2
550
3885
JN5AN
NOMESCO Finland
Total body isotope imaging
45.2
15.1
18
*
YN1AD
NOMESCO Finland
CT examination of extremities for dose design of radiotherapy
11.8
15.0
27
23
OAB75
NOMESCO Finland
Nutritional guidance related to maintaining health
31.8
14.8
19
6
SPAT1203
SPAT
Injection therapy, other than intramuscular or subcutaneous
2.1
14.7
141
688
JN3BD
NOMESCO Finland
Extensive abdominal CT
1.6
14.7
355
2293
L95
ICPC
Osteoporosis
3.0
14.6
62
206
G04BE09
ATC
vardenafil; oral
5.5
14.3
27
49
XX2RW, ,
NOMESCO Finland
3.5
14.2
47
134
U28
ICPC
Limited function/disability (U)
2.7
13.8
75
285
WC225
NOMESCO Finland
Demanding therapy of local tumor recidive with hormone
53.5
13.8
16
*
ZY020
NOMESCO Finland
Telephone, letter or other consultation without direct patient contact
1.8
13.7
212
1216
B02AA02
ATC
tranexamic acid; systemic
1.7
13.6
253
1528
Z43.5
ICD-10 Finland
Attention to cystostomy
3.1
13.6
56
183
KDV10
NOMESCO Finland
Internal urethrotomy
2.3
13.2
103
463
TKD00
NOMESCO Finland
Dilatation of urethra
3.3
13.1
48
146
TQB05
NOMESCO Finland
Puncture of skin of trunk
6.1
12.9
22
36
NA049
NOMESCO Finland
Radiotherapy of methastasis in spine
19.1
12.9
19
10
ECB20
NOMESCO Finland
Oral alveoplasty
3.1
12.8
53
174
U07
ICPC
Urine symptom/complaint other
1.7
12.7
237
1434
KDE20
NOMESCO Finland
Removal of foreign body from urethra
2.7
12.6
68
258
J01CA08
ATC
pivmecillinam; oral
1.6
12.6
292
1867
2AE02, ,
NOMESCO Finland
70.1
12.6
14
*
YG1AD
NOMESCO Finland
CT examination of thorax for dose design of radiotherapy
3.3
12.6
46
140
U13
ICPC
Bladder symptom/complaint other
2.3
12.3
96
432
C05AA08
ATC
fluocortolone; rectal, topical
1.5
12.2
418
2913
M05BA02
ATC
clodronic acid; systemic
4.3
12.2
31
73
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
2.4
12.0
78
325
UJF45
NOMESCO Finland
Flexible sigmoidoscopy with biopsy
1.6
11.9
298
1941
JN2AE
NOMESCO Finland
Ultrasound examination of lower part of abdomen without contrast
3.0
11.9
50
166
KEW98
NOMESCO Finland
Other transluminal endoscopic operation on prostate
22.9
11.6
16
7
Y99
ICPC
Genital disease male other
9.2
11.5
23
25
ZXE10
NOMESCO Finland
More than one and less than three hours
1.3
11.5
1180
9813
AA1BD
NOMESCO Finland
Extensive CT of head and brain
2.2
11.4
99
466
Z51.88
ICD-10 Finland
Other specified medical care
2.3
11.3
82
358
OAB77
NOMESCO Finland
Discussion on exercise habits and instruction concerning use of sports and fitness services
15.1
11.3
18
12
A98
ICPC
Health maint/preventive medicine
1.3
11.0
3001
28073
JN4CD
NOMESCO Finland
Very extensive body CT
1.8
11.0
164
931
C77.1
ICD-10 Finland
Secondary and unspecified malignant neoplasm: Intrathoracic lymph nodes
4.7
10.9
25
54
KGH10
NOMESCO Finland
Operation for phimosis
1.8
10.8
148
820
YJ1AD
NOMESCO Finland
CT examination of abdomen for dose design of radiotherapy
5.6
10.7
20
36
C03CA01
ATC
furosemide; systemic
1.3
10.7
1534
13262
J44.8
ICD-10 Finland
Other specified chronic obstructive pulmonary disease
0.7
10.7
348
4922
N99.1
ICD-10 Finland
Postprocedural urethral stricture
2.8
10.6
52
188
K62.5
ICD-10 Finland
Haemorrhage of anus and rectum
1.7
10.6
198
1200
Z2221
NOMESCO Finland
Medical doctor
1.3
10.5
817
6532
A04AA55
ATC
palonosetron, combinations; systemic
2.8
10.4
52
190
SAA03
NOMESCO Finland
Extended examination of mouth
1.3
10.3
894
7255
ZXA10
NOMESCO Finland
Bilateral
1.4
10.2
612
4708
NF3AA
NOMESCO Finland
Femur X-ray examination
2.2
10.1
82
376
TQX20
NOMESCO Finland
Implantation of subcutaneous medicament implant
8.4
10.0
21
25
N30.0
ICD-10 Finland
Acute cystitis
1.5
10.0
297
2010
SPAT1255
SPAT
Intravenous administration of medicine
1.6
9.9
259
1703
R06AE07
ATC
cetirizine; oral
1.3
9.9
926
7580
XX9AW
NOMESCO Finland
Production of copy from X-ray picture
2.2
9.9
77
348
NA3DG
NOMESCO Finland
Lumbar spine very extensive MRI examination with high intensity magnet
3.4
9.9
34
100
XX9BW
NOMESCO Finland
Submitting image material and/or investigation material to authority or other institution
3.0
9.8
42
141
M04AA01
ATC
allopurinol; systemic
0.7
9.7
443
5914
KE1DG
NOMESCO Finland
Very extensive MRI of prostate
2.6
9.7
56
221
C79.1
ICD-10 Finland
Secondary malignant neoplasm of bladder and other and unspecified urinary organs
100.3
9.4
10
*
ZXF10
NOMESCO Finland
Interruption caused by technical failure of equipment
8.0
9.3
20
25
KBV12
NOMESCO Finland
Transluminal endoscopic removal of stent from ureter
2.4
9.3
62
262
NA2CG
NOMESCO Finland
Thoracal spine extensive MRI examination with high intensity magnet
3.5
9.2
30
85
NE1AA
NOMESCO Finland
Pelvis X-ray examination
1.5
9.2
260
1741
R39.1
ICD-10 Finland
Other difficulties with micturition
1.7
9.2
154
907
J01CR02
ATC
amoxicillin and beta-lactamase inhibitor; systemic
1.2
9.1
1394
12077
JN2DG
NOMESCO Finland
Very extensive MRI examination of lower part of abdoment with high intensity magnet
5.0
9.1
19
38
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
1.4
9.1
474
3563
EB1WA, ,
NOMESCO Finland
3.8
9.0
27
72
NE049
NOMESCO Finland
Radiotherapy of methastasis in pelvis, sacrum or coggyx
36.8
9.0
11
*
U05
ICPC
Urination problems other
1.6
9.0
214
1378
A29
ICPC
General symptom/complaint other
1.4
9.0
413
3038
ZXD10
NOMESCO Finland
Scheduled procedure
1.3
9.0
1218
10408
U29
ICPC
Urinary symptom/complaint other
1.9
9.0
107
568
KC1AT
NOMESCO Finland
Puncture of urinary bladder with ultrasound guidance
4.3
8.9
22
51
WZB00
NOMESCO Finland
Telephone prescription or other care instructions
1.3
8.8
642
5073
EB1CI
NOMESCO Finland
Cone beam imaging of teeth and jaws (3-4 quarters)
3.1
8.8
36
118
U50
ICPC
Urological, Medication/prescr/renewal
10.7
8.8
16
15
Z08.2
ICD-10 Finland
Follow-up examination after chemotherapy for malignant neoplasm
10.7
8.8
16
15
C78.0
ICD-10 Finland
Secondary malignant neoplasm of lung
2.1
8.8
80
386
D630, C61,
ICD-10 Finland
50.1
8.7
10
*
N05CF01
ATC
zopiclone; oral
1.3
8.7
1063
8972
D07.5
ICD-10 Finland
Carcinoma in situ: Prostate
7.6
8.6
19
25
7461
FHL
Needle biopsy in the operating room
3.2
8.6
33
104
KEC10
NOMESCO Finland
Perineal radical prostatectomy
11.6
8.6
15
13
JN3CD
NOMESCO Finland
Abdominal CT examination both without and with contrast
1.7
8.5
145
858
U06
ICPC
Haematuria
1.7
8.5
135
784
ZX100
NOMESCO Finland
Oral
2.3
8.5
63
280
EBA10
NOMESCO Finland
Operative extraction of tooth
1.5
8.4
233
1554
D40.9
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Male genital organ, unspecified
4.3
8.4
21
49
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
1.4
8.4
361
2626
U99
ICPC
Urinary disease other
2.7
8.4
44
166
SAA02
NOMESCO Finland
Basic examination of mouth
1.2
8.3
1521
13392
L02AB02
ATC
medroxyprogesterone; systemic
8.5
8.3
17
20
C78.7
ICD-10 Finland
Secondary malignant neoplasm of liver and intrahepatic bile duct
1.9
8.2
105
570
I89.0
ICD-10 Finland
Lymphoedema, not elsewhere classified
3.8
8.2
24
63
J01MA06
ATC
norfloxacin; oral
1.5
8.1
299
2113
KDW96
NOMESCO Finland
Other operations on urethra
4.5
8.1
19
42
Y55
ICPC
Male Genital, Local injection/infiltration
33.4
8.1
10
*
J01MA01
ATC
ofloxacin; systemic
1.4
8.0
331
2390
KC1AE
NOMESCO Finland
Percutaneous ultrasound examination of urinary bladder
4.1
8.0
21
51
PJD54
NOMESCO Finland
Block dissection of iliac lymph nodes
3.1
8.0
32
104
7455
FHL
Retropubic total prostatectomy
9.4
7.8
15
16
A21
ICPC
Risk factor for malignancy
7.4
7.7
17
23
Z93.6
ICD-10 Finland
Other artificial openings of urinary tract status
7.4
7.7
17
23
G04CA01
ATC
alfuzosin; oral
1.3
7.6
846
7045
Y26
ICPC
Fear of genital cancer male
10.0
7.5
14
14
G04CB01
ATC
finasteride; oral
0.8
7.5
648
7929
WX110
NOMESCO Finland
Infiltration anesthesia
1.2
7.5
1926
17474
WPA15
NOMESCO Finland
Palliative care consultation with the patient and loved ones
3.9
7.4
21
54
WPB10
NOMESCO Finland
Making a convalescent care decision
4.0
7.3
20
50
U79
ICPC
Neoplasm urinary tract unspecified
10.9
7.3
13
12
G04CB02
ATC
dutasteride; oral
0.7
7.3
355
4703
I25.1
ICD-10 Finland
Atherosclerotic heart disease
0.8
7.3
991
11526
103
Kela drug reimbursment
Diabetes, insulin-treated
0.8
7.2
829
9816
YN7VG
NOMESCO Finland
MRI examination of spine with high intesinty magnet for dose design of radiotherapy
30.1
7.1
9
*
N13.1
ICD-10 Finland
Hydronephrosis with ureteral stricture, not elsewhere classified
4.1
7.1
19
47
A10BB01
ATC
glibenclamide; oral
0.6
7.0
104
1758
XKD11, ,
NOMESCO Finland
10.0
7.0
13
13
N21.0
ICD-10 Finland
Calculus in bladder
2.0
7.0
67
330
L28
ICPC
Limited function/disability (L)
1.3
7.0
628
5090
G04BD07
ATC
tolterodine; oral
1.6
7.0
152
960
SPAT1245
SPAT
Provision of support and information to patient’s family members
1.5
7.0
201
1353
OAA41
NOMESCO Finland
Health check based on individual needs
7.0
7.0
16
23
JGA28
NOMESCO Finland
Endoscopic contact coagulation in rectum
5.5
6.9
19
35
A07DA03
ATC
loperamide; oral
1.7
6.9
123
739
R4110
NOMESCO Finland
Physiotherapy
1.2
6.8
817
6853
XX9CN, ,
NOMESCO Finland
40.1
6.8
8
*
F03
ICD-10 Finland
Unspecified dementia
0.6
6.8
89
1551
JN2BD
NOMESCO Finland
Extensive CT exmaniation of lower part of abdomen
5.6
6.7
18
32
GD1AA
NOMESCO Finland
Thorax X-ray examination
1.2
6.7
1705
15385
TQW40
NOMESCO Finland
Remowal of suture of skin
1.5
6.7
183
1218
A41.8
ICD-10 Finland
Other specified sepsis
1.9
6.7
86
469
WZC10
NOMESCO Finland
Written specialist consultation based on a referral from a dentist or a physician
1.7
6.7
121
730
C01DA08
ATC
isosorbide dinitrate; oral, oral aerosol, sublingual, transdermal
0.8
6.7
890
10397
N30.9
ICD-10 Finland
Cystitis, unspecified
1.6
6.6
133
824
HAC20
NOMESCO Finland
Total mastectomy
6.4
6.6
16
25
I21.9
ICD-10 Finland
Acute myocardial infarction, unspecified
0.4
6.6
30
760
WB221
NOMESCO Finland
Demanding neoadjuvant hormone therapy of malignancy
3.6
6.6
21
59
8010/3-C61.9
ICD-O-3
Carcinoma, NOS, of prostate gland
10.0
6.5
12
12
L02BA01
ATC
tamoxifen; oral
6.2
6.5
16
26
NK6CT
NOMESCO Finland
Bone biopsy with CT guidance
3.9
6.4
18
46
JR2PR, ,
NOMESCO Finland
70.0
6.4
7
*
M907, C61,
ICD-10 Finland
70.0
6.4
7
*
SPAT1262
SPAT
Handing over of treatment supplies
1.3
6.4
668
5515
ZX114
NOMESCO Finland
Intramuscular
2.5
6.3
36
142
Z50.1
ICD-10 Finland
Other physical therapy
1.6
6.3
150
970
ZX022
NOMESCO Finland
LDR radiotherapy within tissue
5.5
6.3
17
31
B01AB04
ATC
dalteparin; parenteral
1.5
6.2
163
1076
WVA20
NOMESCO Finland
Medicine administration
1.9
6.2
79
430
R60.0
ICD-10 Finland
Localized oedema
1.3
6.2
399
3094
203
Kela drug reimbursment
Chronic asthma and similar chronic obstructive pulmonary diseases
0.8
6.2
393
5013
N05AD01
ATC
haloperidol; systemic
1.6
6.1
123
763
K10.20
ICD-10 Finland
Osteomyelitis (neonatal) of jaw (acute)(chronic)(suppurative)
7.7
6.1
13
17
B01AE07
ATC
dabigatran etexilate; oral
1.5
6.1
156
1027
J44.0
ICD-10 Finland
Chronic obstructive pulmonary disease with acute lower respiratory infection
0.6
6.0
122
1906
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
1648
2966
9.03
307.65
2.7
2.0
4.02
12.87
nmol/l
215.36
1383
2525
1730
9774
2.41
148.69
8.6
3.2
2.34
2.33
mmol/l
3.32
1616
8338
2389
15861
2.36
137.23
13.4
6.2
10.54
13.58
umol/l
44.05
2328
15064
2991
22251
2.60
128.29
17.2
7.7
92.08
81.91
u/l
9.95
2928
20832
1724
10613
2.14
110.84
4.4
3.7
205.63
132.90
e6/l
0.43
1499
8548
3016
23171
2.45
109.34
18.1
5.2
26.37
3.12
ug/l
17.31
2865
20349
2265
15803
2.07
100.35
11.1
7.3
1.21
1.20
mmol/l
4.83
1961
13296
1786
11508
2.04
97.80
4.9
4.1
124.87
106.01
e6/l
0.30
1530
8934
2610
19344
2.11
96.13
5.9
4.6
231.72
988.35
e6/l
1.24
75
388
2524
18524
2.08
94.79
10.1
4.6
19.12
22.37
%
19.26
1794
9969
2249
16121
1.97
86.65
15.0
8.3
4.21
4.59
e9/l
11.21
2021
13902
1918
13053
1.95
85.98
5.3
3.3
1.65
0.80
ug/l
20.50
1492
9552
1516
9565
1.97
84.64
4.2
3.6
0.38
0.49
e6/l
0.97
1318
7605
1273
7592
2.02
83.24
3.1
2.8
2.81
2.87
e6/l
0.14
1178
6829
961
5558
1.98
65.93
3.9
3.5
0.76
0.71
e6/l
0.34
642
3366
1977
14447
1.77
62.82
8.5
6.5
1.21
1.20
mmol/l
8.20
1893
13032
955
5841
1.85
53.60
4.9
3.2
2.46
2.45
mmol/l
1.46
874
5015
947
5842
1.83
51.37
3.6
3.2
0.91
0.95
e6/l
0.20
633
3618
1861
13894
1.66
50.30
5.9
5.2
33.99
34.01
g/l
0.04
1753
12770
790
4743
1.84
46.17
6.0
3.9
270.54
244.05
u/l
2.60
754
4433
1207
8511
1.61
37.95
4.8
3.2
34.85
39.03
u/l
0.85
1159
7969
1756
13819
1.50
32.15
3.3
2.9
—
—
—
0
0
405
2200
1.94
31.41
3.9
3.2
0.22
0.28
e6/l
0.85
397
2170
2999
26721
1.58
27.94
24.6
19.5
33.99
31.13
mg/l
3.68
2665
22460
2528
21856
1.47
26.04
32.7
22.6
14.90
15.60
%
10.66
2494
21382
447
2659
1.77
25.74
6.7
4.2
1.21
1.21
mmol/l
0.35
418
2318
1525
12063
1.44
25.07
14.5
10.9
0.01
0.00
e9/l
0.62
1268
9806
1683
13657
1.42
23.52
5.9
6.0
22.87
24.47
%
6.93
1579
12645
2205
18839
1.40
22.41
4.9
5.3
6.95
7.03
mmol/l
0.84
2120
17854
2071
17508
1.40
22.38
17.0
22.2
1.30
1.46
inr
11.38
624
4904
1634
13411
1.38
20.33
5.8
5.7
61.17
59.65
%
5.10
1530
12420
1632
13478
1.37
19.15
5.8
6.2
9.03
9.17
%
0.87
1523
12456
1646
13617
1.37
19.08
4.2
3.7
0.00
0.00
estimate
-0.00
343
2503
1622
13394
1.37
18.99
5.5
4.9
0.00
0.00
estimate
-0.00
352
2661
1622
13414
1.36
18.73
5.6
5.8
2.82
2.92
%
0.71
1513
12382
3090
28378
1.47
18.62
27.4
23.7
4.02
4.05
mmol/l
6.85
3033
27549
3045
27892
1.46
18.55
17.9
11.4
22.50
26.66
u/l
21.39
2963
26538
3086
28343
1.47
18.51
27.0
23.5
139.32
139.59
mmol/l
7.41
3031
27547
2760
24851
1.40
18.42
28.7
18.6
73.42
70.80
ml/min/173m2
9.99
2469
20853
1579
13036
1.36
18.29
5.7
5.8
0.56
0.61
%
3.06
1474
12035
3114
28685
1.47
18.06
38.8
28.4
37.49
39.80
%
58.27
2877
26196
1627
13517
1.36
18.00
4.2
3.7
0.00
0.00
estimate
0.06
375
2856
3115
28701
1.47
18.00
38.8
28.2
6.73
7.20
e9/l
20.53
3047
27591
3114
28695
1.47
17.93
38.8
28.2
4.18
4.43
e12/l
111.69
3043
27585
3114
28700
1.47
17.87
39.1
28.4
126.59
134.87
g/l
133.60
3071
28057
3113
28691
1.47
17.84
39.0
28.2
228.87
223.85
e9/l
4.27
3054
27701
994
7692
1.40
16.90
4.8
4.4
85.77
77.94
%
17.63
978
7513
1693
14448
1.31
14.42
6.0
5.5
1.59
1.87
e9/l
4.50
1463
12540
1699
14615
1.29
13.22
5.9
5.6
0.19
0.21
e9/l
5.49
1446
12598
1258
10397
1.31
13.22
4.6
4.0
—
—
—
0
0
1122
9146
1.32
12.96
2.0
2.3
3.06
3.07
mg/l
0.02
944
7674
808
6344
1.35
11.92
1.9
1.9
—
—
—
0
0
1637
14157
1.27
11.71
5.8
5.4
0.62
0.67
e9/l
7.16
1371
12049
711
5503
1.36
11.47
2.1
2.7
2.13
2.19
g/l
2.09
663
5041
1641
14226
1.27
11.40
5.8
5.4
0.03
0.04
e9/l
10.59
1370
12124
751
5879
1.35
11.23
2.2
2.7
12.04
12.10
umol/l
0.07
705
5419
286
1897
1.55
10.55
1.9
1.9
3.43
2.44
ug/l
0.31
255
1629
672
5251
1.34
10.07
2.2
2.8
22.70
22.16
%
0.47
572
4425
887
10750
0.77
10.00
3.0
3.3
7.50
8.00
mmol/l
3.30
699
8771
886
10712
0.77
9.74
3.0
3.4
210.18
318.91
mg/l
0.56
611
7473
699
5518
1.33
9.73
2.9
3.2
0.82
0.82
mmol/l
0.68
667
5126
948
11339
0.78
9.50
3.6
4.0
8.86
10.73
mg/mmol
0.86
636
7699
563
4328
1.35
9.35
1.9
1.8
—
—
—
0
0
919
7604
1.27
8.88
3.1
2.7
—
—
—
0
0
559
4354
1.33
8.46
1.9
1.8
—
—
—
0
0
1295
11198
1.24
8.44
2.6
3.0
365.38
192.14
ug/l
12.75
1174
10008
84
420
2.02
8.37
2.0
1.2
—
—
—
0
0
291
4051
0.70
8.06
10.5
9.1
—
—
—
0
0
279
3886
0.70
7.75
4.2
5.0
31.21
32.76
%
1.53
185
2604
480
3714
1.33
7.57
3.3
4.0
1.55
1.80
mmol/l
0.60
374
3057
340
2516
1.39
7.14
1.5
1.7
—
—
—
0
0
475
3717
1.32
6.91
3.3
4.0
5.64
5.83
kpa
3.37
465
3579
1729
15615
1.20
6.79
3.4
3.3
58.19
63.13
u/l
1.04
1596
14054
806
6754
1.25
6.76
3.7
4.4
1415.31
506.59
ng/l
0.42
714
6065
294
3946
0.72
6.53
1.2
1.2
1.89
2.01
u/ml
0.08
62
948
551
6768
0.78
6.46
1.7
1.6
1.38
1.29
mmol/l
1.65
442
5491
470
3745
1.29
5.97
3.3
4.1
26.32
27.56
ug/l
0.04
390
3176
439
3468
1.30
5.95
3.0
2.9
8.16
10.81
umol/l
1.37
393
3073
455
3618
1.29
5.87
2.9
3.1
231.63
278.14
ng/l
1.52
428
3353
901
7760
1.21
5.69
4.6
4.0
0.01
0.00
estimate
0.57
309
2380
38
165
2.32
5.50
2.3
1.5
2.90
7.93
u/l
3.07
30
132
160
1101
1.47
5.09
1.2
1.3
—
—
—
0
0
301
2311
1.33
5.03
1.6
1.5
—
—
—
0
0
778
8973
0.83
4.85
2.7
3.2
6517.46
6030.97
umol/l
0.09
639
7624
1284
11550
1.17
4.78
2.2
2.1
—
—
—
0
0
1313
11835
1.17
4.75
3.3
3.3
2204.19
2125.26
ng/l
0.22
1194
10414
305
2375
1.31
4.63
1.8
1.7
—
—
—
0
0
378
3028
1.28
4.61
2.8
3.3
4.19
4.48
kpa
2.00
362
2904
40
193
2.08
4.55
1.8
3.2
—
—
—
0
0
333
2640
1.29
4.42
2.3
2.5
31.71
38.12
u/l
1.35
276
2243
300
3790
0.77
4.35
1.3
1.5
2.84
2.97
g/l
0.36
170
2233
708
6134
1.19
4.07
4.8
4.1
1.02
1.02
kg/l
0.28
136
958
1068
9577
1.16
4.01
2.5
2.7
55.04
69.60
u/l
1.05
1011
8859
101
667
1.53
3.99
2.2
3.8
2.68
1.57
%
2.10
85
575
31
144
2.16
3.92
1.3
1.1
68.69
110.41
u/l
1.92
26
131
31
144
2.16
3.92
1.3
1.1
37.56
39.94
u/l
0.06
25
130
123
856
1.45
3.78
1.5
1.3
—
—
—
0
0
123
856
1.45
3.78
1.5
1.3
—
—
—
0
0
1656
17775
0.88
3.75
3.0
3.1
15.10
15.07
pmol/l
0.15
1468
15479
255
2009
1.29
3.60
3.5
3.7
25.04
24.89
mmol/l
0.23
249
1941
238
3006
0.78
3.48
1.2
1.2
12.52
16.06
u/ml
0.27
71
1008
36
651
0.55
3.29
1.3
1.5
—
—
—
0
0
118
1607
0.73
2.98
2.7
2.7
—
—
—
0
0
181
2307
0.77
2.88
1.7
1.7
1.66
1.72
%
0.35
152
1855
207
1638
1.28
2.88
3.7
5.2
0.83
0.86
%
0.59
194
1536
927
8403
1.14
2.86
1.7
1.6
16.99
18.77
nmol/l
4.01
819
7132
579
5078
1.17
2.85
2.7
2.3
1.73
1.72
%
0.17
521
4405
120
886
1.37
2.73
2.0
2.7
14.36
15.91
%
3.06
59
487
41
676
0.60
2.72
1.6
1.6
10.39
12.89
mg/l
1.04
35
612
7
200
0.35
2.65
1.0
1.1
—
25.00
—
0
8
44
707
0.62
2.63
1.5
1.6
0.20
17.98
iu/ml
1.27
11
189
648
5777
1.15
2.56
1.6
1.7
2.27
1.71
mg/l
1.65
519
4583
81
566
1.44
2.55
1.2
1.6
—
—
—
0
0
81
566
1.44
2.55
1.2
1.6
—
—
—
0
0
119
891
1.35
2.51
1.3
1.6
—
—
—
0
0
285
2379
1.21
2.49
2.5
3.9
1.39
0.68
%
2.34
144
905
78
1098
0.70
2.46
1.6
1.6
37.44
36.68
u/l
0.11
66
903
285
2384
1.21
2.45
3.3
3.6
118.89
128.01
g/l
9.72
278
2319
206
1671
1.25
2.38
3.7
5.1
1.50
1.64
%
2.06
193
1568
81
577
1.41
2.33
2.5
2.1
32.05
33.04
pg
1.22
81
572
1415
13280
1.10
2.29
4.2
4.5
51.25
82.20
ng/l
1.44
1200
10861
546
4848
1.15
2.29
4.5
6.4
1.02
1.03
mmol/l
0.40
507
4474
6
171
0.35
2.26
1.2
1.1
—
—
—
0
0
19
366
0.52
2.24
1.1
1.1
—
—
—
0
0
163
2033
0.79
2.23
2.2
2.5
10.09
10.89
g/l
1.83
144
1844
28
477
0.58
2.17
1.2
1.2
6.80
3.31
u/ml
—
5
54
64
902
0.70
2.08
3.0
3.0
0.87
0.83
nmol/l
0.26
48
674
279
3265
0.84
2.04
1.2
1.2
36.47
44.73
iu/ml
0.39
93
933
439
3872
1.15
2.04
5.1
7.2
11.76
11.98
mmol/l
0.23
413
3639
2250
23327
0.91
2.03
3.6
4.0
2.20
2.11
mu/l
0.57
1983
20459
2542
26205
0.91
2.03
4.9
5.6
2.55
2.37
mmol/l
17.22
2237
23423
71
509
1.40
2.01
1.6
1.9
86.65
88.53
%
1.00
71
503
47
311
1.52
2.00
1.7
2.0
3.41
1.51
u/field
0.70
22
116
55
378
1.46
1.96
1.2
1.4
—
—
—
0
0
55
378
1.46
1.96
1.2
1.4
—
—
—
0
0
28
457
0.61
1.88
1.5
1.6
3.10
3.38
mg/l
0.09
22
336
1062
9914
1.10
1.86
1.9
2.1
82.01
76.82
nmol/l
6.66
935
8469
110
857
1.29
1.84
1.3
1.6
—
—
—
0
0
95
730
1.31
1.77
2.7
2.3
219.24
211.06
%
0.33
90
693
116
1454
0.79
1.72
2.3
2.4
47.65
15.13
au/ml
—
6
57
413
3674
1.14
1.72
3.9
4.0
—
—
—
0
0
289
2507
1.17
1.71
4.4
2.9
62.80
59.22
ml/min/173m2
0.89
132
1078
28
445
0.63
1.71
1.2
1.3
—
—
—
0
0
52
729
0.71
1.70
1.2
1.2
—
240.00
—
0
21
34
514
0.66
1.66
2.5
1.3
8.18
8.15
u/l
0.01
18
416
59
805
0.73
1.64
1.4
1.5
21145.09
16786.95
e6/l
0.28
35
577
130
1597
0.81
1.63
1.5
1.9
0.94
1.42
g/l
4.26
111
1420
96
749
1.29
1.62
4.1
3.8
28.70
33.64
mg/l
0.81
73
509
51
710
0.71
1.61
1.0
1.1
—
1.68
—
0
11
105
1318
0.79
1.60
1.2
1.3
98.37
71.03
au/ml
—
6
74
134
1634
0.81
1.57
3.1
4.4
24.22
24.65
mmol/l
0.95
116
1482
21
349
0.60
1.56
1.4
1.3
111506.43
149755.62
e6/l
0.13
14
244
113
907
1.25
1.53
3.4
5.1
2.26
2.56
mmol/l
0.63
67
609
11
220
0.50
1.53
1.0
1.1
—
2.06
—
0
8
0
44
0.00
1.51
0.0
1.1
—
—
—
0
0
71
539
1.32
1.48
5.5
6.6
13.58
11.95
mg/l
1.88
66
491
198
1690
1.18
1.47
1.9
2.0
—
—
—
0
0
73
945
0.77
1.45
1.2
1.3
—
—
—
0
0
113
916
1.24
1.43
2.1
2.3
116.46
128.35
g/l
4.91
85
674
34
496
0.68
1.43
1.2
1.2
—
50.89
—
0
14
57
422
1.36
1.42
1.4
1.6
—
—
—
0
0
12
226
0.53
1.41
1.1
1.1
—
—
—
0
0
66
862
0.76
1.41
2.4
2.6
2.00
1.86
mg/l
0.51
59
749
211
1820
1.17
1.39
2.2
2.8
1.13
1.18
%
0.37
206
1812
35
504
0.69
1.38
1.3
1.3
—
—
—
0
0
207
1786
1.17
1.36
2.2
2.7
0.69
0.65
%
1.11
202
1779
43
592
0.72
1.32
1.8
1.8
104.91
196.30
pmol/l
4.97
35
542
36
510
0.70
1.31
1.3
1.3
6.08
32.08
e6/l
1.22
24
408
20
121
1.66
1.30
2.3
2.1
—
—
—
0
0
20
121
1.66
1.30
2.3
2.1
—
—
—
0
0
37
259
1.43
1.29
1.2
1.5
—
—
—
0
0
89
1103
0.80
1.27
1.3
1.3
480.32
319.45
u/ml
0.43
83
992
31
448
0.69
1.27
1.0
1.1
—
—
—
0
0
2479
25381
0.93
1.26
4.4
4.9
4.38
4.11
mmol/l
31.68
2191
22839
2454
25129
0.93
1.24
4.3
4.9
1.35
1.30
mmol/l
9.09
2154
22379
340
3769
0.89
1.23
2.5
2.4
7.18
7.15
ug/l
0.01
298
3245
82
655
1.26
1.22
1.3
1.7
—
—
—
0
0
220
2498
0.87
1.18
7.7
9.0
93.67
93.72
%
0.04
220
2485
26
382
0.68
1.18
2.5
2.2
—
0.15
—
0
5
2384
24414
0.94
1.17
3.9
4.4
1.32
1.25
mmol/l
4.66
2062
21569
37
509
0.72
1.16
1.3
1.4
644.89
906.85
e6/l
0.18
28
424
6
127
0.47
1.16
1.2
1.7
0.18
-0.02
mmol/l
—
6
118
28
191
1.47
1.13
2.0
1.8
3.80
2.00
u/field
0.65
20
127
43
575
0.74
1.13
1.1
1.3
0.91
0.82
nmol/l
0.35
33
475
245
2176
1.13
1.12
1.4
1.6
1.76
1.53
g/l
2.38
206
1835
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
191
1670
1.15
1.10
2.5
2.7
0.31
0.33
u/ml
0.45
99
942
179
1559
1.16
1.09
1.8
1.9
—
—
—
0
0
16
255
0.63
1.07
1.0
1.0
328.44
326.22
ng/l
—
9
161
16
255
0.63
1.07
1.0
1.0
794.50
639.39
ng/l
—
8
156
16
255
0.63
1.07
1.0
1.0
38.66
44.39
ng/l
—
9
156
35
254
1.38
1.04
1.2
1.5
—
—
—
0
0
104
870
1.20
1.04
1.9
2.2
4.04
3.65
g/l
1.41
97
814
67
833
0.80
1.03
1.6
2.4
31.23
34.09
umol/l
0.49
60
736
44
576
0.76
1.02
1.1
1.1
—
—
—
0
0
72
581
1.24
1.02
1.3
1.3
—
—
—
0
0
126
1462
0.86
0.95
2.6
4.1
1.48
1.49
mmol/l
0.03
121
1439
6
28
2.14
0.91
1.2
1.2
16.33
11.39
u/l
—
6
28
90
1069
0.84
0.91
1.8
2.2
208.81
115.66
ug/min
0.60
51
618
187
2101
0.88
0.90
1.9
2.2
181.07
186.20
ug/g
0.04
148
1652
40
305
1.31
0.90
3.4
1.3
224.57
252.50
pmol/l
0.36
35
243
12
194
0.62
0.89
1.4
1.5
3.28
1.82
%
0.37
12
165
10
169
0.59
0.88
1.6
1.4
26.56
19.18
%
—
10
155
623
5877
1.07
0.86
2.1
2.0
30.25
30.55
s
0.60
601
5708
126
1448
0.87
0.86
2.3
3.2
52.21
69.05
mg/l
1.41
101
1174
11
180
0.61
0.86
2.0
2.3
0.17
0.25
e9/l
1.75
11
164
12
192
0.62
0.85
1.0
1.1
—
—
—
0
0
126
1446
0.87
0.85
2.3
3.2
38.34
60.32
mg/l
1.21
102
1179
38
291
1.31
0.84
1.5
1.5
—
—
—
0
0
147
1297
1.14
0.81
3.1
3.5
192.45
4120.53
u/ml
1.13
127
1114
370
3432
1.09
0.80
5.5
6.8
1.32
1.44
mmol/l
2.07
359
3308
64
527
1.22
0.80
1.4
1.5
—
—
—
0
0
18
259
0.69
0.79
2.7
3.2
—
—
—
0
0
10
58
1.73
0.79
1.2
1.4
117.90
461.03
nmol/24h
—
10
58
6
33
1.82
0.79
1.0
1.1
—
—
—
0
0
9
147
0.61
0.79
1.1
1.1
206.67
288.40
u/l
—
9
136
26
190
1.37
0.78
1.0
1.3
—
—
—
0
0
26
190
1.37
0.78
1.0
1.3
—
—
—
0
0
11
175
0.63
0.78
1.0
1.0
—
—
—
0
0
7
123
0.57
0.77
1.0
1.2
—
62.39
%
—
0
18
26
191
1.36
0.77
1.1
2.0
—
—
—
0
0
26
191
1.36
0.77
1.1
2.0
—
—
—
0
0
22
303
0.72
0.76
1.3
1.3
—
—
—
0
0
0
28
0.00
0.76
0.0
1.0
—
—
—
0
0
365
3396
1.08
0.75
2.9
2.5
65.76
65.79
g/l
0.03
328
3020
125
1417
0.88
0.73
2.3
3.2
5.72
4.15
ratio
—
9
104
68
806
0.84
0.72
1.1
1.1
108.32
90.62
iu/ml
0.12
22
229
51
416
1.23
0.71
2.2
3.9
62.84
58.11
%
0.90
38
336
35
274
1.28
0.69
1.3
1.4
—
—
—
0
0
66
778
0.85
0.67
1.5
1.5
29.60
31.11
g/l
0.51
57
685
5
95
0.53
0.66
1.0
1.1
—
—
—
0
0
5
95
0.53
0.66
2.2
2.9
15.48
14.72
ml/dl
—
5
90
15
213
0.70
0.64
1.1
1.2
—
117.50
—
0
8
15
213
0.70
0.64
1.1
1.2
68.00
111.94
titre
—
5
31
18
247
0.73
0.64
2.4
2.1
87.89
212.10
ug/min
—
9
67
8
128
0.62
0.64
1.0
1.1
—
—
—
0
0
8
128
0.62
0.64
1.0
1.1
—
—
—
0
0
8
129
0.62
0.63
1.0
1.1
—
—
—
0
0
8
130
0.61
0.63
1.0
1.1
—
—
—
0
0
8
130
0.61
0.63
1.0
1.1
—
—
—
0
0
8
130
0.61
0.63
1.0
1.1
—
—
—
0
0
15
104
1.44
0.62
1.3
1.2
—
—
—
0
0
45
545
0.82
0.62
1.3
1.3
—
—
—
0
0
0
21
0.00
0.60
0.0
1.0
—
—
—
0
0
0
22
0.00
0.59
0.0
4.3
—
—
—
0
0
200
1837
1.09
0.59
1.2
1.2
—
—
—
0
0
67
778
0.86
0.59
1.8
3.3
67.30
665.80
u/ml
2.23
57
718
0
23
0.00
0.58
0.0
1.0
—
—
—
0
0
6
35
1.72
0.57
1.0
1.0
—
—
—
0
0
134
1480
0.90
0.55
1.8
2.3
3.19
2.92
g/l
2.01
117
1289
99
879
1.13
0.55
4.3
6.8
103.74
105.30
mmol/l
2.37
88
787
76
663
1.15
0.55
1.2
1.4
—
—
—
0
0
26
328
0.79
0.54
1.7
1.1
—
—
—
0
0
20
151
1.33
0.53
1.2
2.1
—
—
—
0
0
9
135
0.67
0.51
1.0
1.0
—
—
—
0
0
17
126
1.35
0.51
1.3
1.3
—
—
—
0
0
233
2496
0.93
0.50
7.3
8.9
0.62
0.65
%
0.58
228
2472
24
189
1.27
0.49
1.3
1.4
57.25
155.57
pmol/l
4.38
24
189
407
3875
1.06
0.48
2.9
2.5
64.55
66.59
e9/l
0.72
318
3038
88
984
0.89
0.47
1.5
1.6
—
—
—
0
0
24
299
0.80
0.46
1.4
1.3
275.00
279.83
mosm/kgh2o
0.44
16
225
45
383
1.18
0.46
1.2
1.5
—
—
—
0
0
19
243
0.78
0.45
1.2
1.3
—
95.00
—
0
26
64
727
0.88
0.45
1.1
1.1
—
—
—
0
0
47
403
1.17
0.45
2.1
3.3
—
—
—
0
0
16
209
0.76
0.45
1.6
1.1
2.55
2.15
mmol/l
0.65
16
192
8
56
1.43
0.42
1.4
1.1
—
—
—
0
0
68
603
1.13
0.42
2.2
4.9
215.80
4449.24
iu/ml
—
5
94
76
848
0.89
0.41
1.8
2.0
—
—
—
0
0
35
295
1.19
0.41
1.2
1.2
1.25
5.21
u/ml
0.99
16
96
45
388
1.16
0.41
1.2
1.5
—
—
—
0
0
0
16
0.00
0.41
0.0
1.1
—
36.58
—
0
6
19
150
1.27
0.40
1.2
2.1
—
—
—
0
0
19
150
1.27
0.40
1.2
2.1
—
—
—
0
0
248
2623
0.94
0.40
2.9
3.8
1.89
1.70
mmol/l
0.29
168
1865
7
103
0.68
0.39
1.1
1.2
—
—
—
0
0
38
325
1.17
0.39
1.3
1.6
8.22
4.12
iu/l
0.44
13
87
0
19
0.00
0.39
0.0
2.1
—
—
—
0
0
73
812
0.90
0.39
1.2
1.5
267.33
252.99
ug/g
0.23
43
522
71
636
1.12
0.39
1.2
1.4
—
—
—
0
0
5
36
1.39
0.38
1.0
1.1
—
—
—
0
0
38
326
1.17
0.38
1.2
1.7
—
—
—
0
0
38
326
1.17
0.38
1.2
1.7
—
—
—
0
0
38
326
1.17
0.38
1.2
1.7
—
—
—
0
0
20
245
0.82
0.36
1.8
1.3
—
—
—
0
0
9
123
0.73
0.35
1.0
1.2
6.61
6.39
mmol/l
—
9
115
45
395
1.14
0.34
1.2
1.5
—
—
—
0
0
262
2748
0.95
0.33
2.9
3.9
4.98
5.11
kpa
1.41
242
2580
6
86
0.70
0.33
2.3
2.2
6.28
8.31
mmol/l
—
6
57
38
331
1.15
0.33
1.4
1.6
—
—
—
0
0
7
52
1.35
0.31
1.0
1.3
—
—
—
0
0
20
165
1.21
0.31
2.1
1.8
—
—
—
0
0
39
442
0.88
0.30
3.7
3.4
—
—
—
0
0
67
610
1.10
0.30
1.2
1.4
—
—
—
0
0
2573
25936
0.98
0.30
4.7
5.4
6.20
6.24
mmol/l
0.92
2273
22851
12
93
1.29
0.30
1.4
2.0
—
—
—
0
0
31
355
0.87
0.28
1.5
1.5
—
—
—
0
0
15
121
1.24
0.28
1.5
1.2
—
—
—
0
0
45
403
1.12
0.27
1.2
1.4
110.36
139.90
u/ml
0.72
11
87
39
346
1.13
0.27
1.2
1.7
—
—
—
0
0
8
65
1.23
0.27
1.0
1.1
—
—
—
0
0
8
65
1.23
0.27
1.0
1.1
—
—
—
0
0
29
253
1.15
0.26
1.0
1.1
—
—
—
0
0
1401
13820
1.02
0.26
2.0
2.2
88.92
89.87
pmol/l
0.34
810
7963
70
645
1.09
0.26
1.2
1.2
—
—
—
0
0
28
320
0.87
0.25
1.4
1.3
21.46
21.51
%
0.00
15
205
58
530
1.10
0.25
1.2
1.2
—
—
—
0
0
9
74
1.22
0.25
1.0
1.2
—
—
—
0
0
153
1610
0.95
0.25
1.7
2.3
7.81
7.33
g/l
2.37
136
1416
17
202
0.84
0.24
1.7
1.9
130.35
105.67
umol/l
0.45
17
202
153
1609
0.95
0.24
1.7
2.3
—
—
—
0
0
40
360
1.11
0.23
1.2
1.7
—
—
—
0
0
2037
20189
1.02
0.23
3.6
4.1
19.09
14.51
mm/h
17.37
1844
18318
153
1605
0.95
0.23
1.7
2.3
4.00
3.74
g/l
0.64
136
1414
115
1216
0.94
0.23
1.5
2.3
37.14
37.01
g/l
0.09
98
1022
5
39
1.28
0.23
1.2
1.7
—
—
—
0
0
79
737
1.07
0.23
1.3
1.2
—
—
—
0
0
69
641
1.08
0.22
1.2
1.2
—
—
—
0
0
22
191
1.15
0.21
1.3
1.5
—
—
—
0
0
22
191
1.15
0.21
1.3
1.5
—
—
—
0
0
10
124
0.81
0.21
1.1
1.7
1.03
0.86
g/l
—
10
124
13
107
1.22
0.21
1.0
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
6.6
—
40.00
—
0
11
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
42.30
—
0
11
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
7.1
—
—
—
0
0
31
277
1.12
0.21
1.8
1.3
0.28
0.17
nmol/l
—
6
24
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
128
1343
0.95
0.20
1.9
2.5
1.04
1.30
g/l
0.30
106
1115
52
563
0.92
0.20
1.7
1.6
—
—
—
0
0
6
48
1.25
0.20
1.8
1.2
69.22
46.99
mg/l
—
6
42
25
221
1.13
0.20
1.0
1.3
—
—
—
0
0
6
49
1.22
0.20
1.0
1.1
—
—
—
0
0
6
49
1.22
0.20
5.0
2.5
0.33
0.20
u/field
—
6
49
20
229
0.87
0.20
1.2
1.3
—
67.00
—
0
20
297
3058
0.97
0.19
2.1
2.2
0.20
0.19
g/l
1.14
272
2795
6
51
1.18
0.19
1.0
1.4
—
—
—
0
0
26
291
0.89
0.19
1.6
1.7
30.00
28.82
u/ml
—
6
62
31
280
1.11
0.18
1.3
1.5
—
—
—
0
0
37
404
0.92
0.18
1.2
1.4
70.40
66.89
%
0.24
23
256
42
387
1.09
0.17
1.2
1.5
—
—
—
0
0
7
62
1.13
0.17
1.7
1.5
80.29
70.89
%
—
7
47
479
4696
1.02
0.17
5.2
7.0
0.59
0.96
mmol/l
1.01
346
3619
8
69
1.16
0.16
1.0
1.1
—
—
—
0
0
42
389
1.08
0.16
1.2
1.5
—
—
—
0
0
42
389
1.08
0.16
1.2
1.5
—
—
—
0
0
53
497
1.07
0.15
1.4
1.6
—
—
—
0
0
11
129
0.85
0.14
2.4
1.2
—
—
—
0
0
991
10018
0.99
0.14
2.3
2.2
230.14
252.57
u/l
0.39
920
9324
54
508
1.06
0.14
9.4
23.1
7.51
7.53
mmol/l
0.02
45
409
422
4297
0.98
0.14
5.6
7.2
94.85
95.09
%
0.26
398
4127
26
237
1.10
0.14
1.3
1.5
—
—
—
0
0
27
294
0.92
0.13
1.2
1.2
—
35.62
—
0
18
12
138
0.87
0.13
1.1
1.1
—
—
—
0
0
26
238
1.09
0.13
1.3
1.5
—
—
—
0
0
51
540
0.94
0.13
1.3
1.3
—
—
—
0
0
11
127
0.87
0.12
1.3
1.3
—
—
—
0
0
11
127
0.87
0.12
1.3
1.3
—
—
—
0
0
22
200
1.10
0.12
1.0
1.0
—
—
—
0
0
17
189
0.90
0.12
2.2
2.3
—
—
—
0
0
2515
25237
0.99
0.10
6.4
7.1
41.16
41.82
mmol/mol
2.97
2270
22714
719
7260
0.99
0.10
2.0
1.8
28020528.33
33424591.88
pmol/l
0.10
596
5870
37
349
1.06
0.10
1.7
2.2
841.91
658.03
ml
1.20
23
210
5
46
1.09
0.09
1.0
1.2
—
—
—
0
0
57
546
1.04
0.09
1.2
1.4
—
—
—
0
0
20
184
1.09
0.09
1.9
1.8
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
14
126
1.11
0.09
1.1
1.1
—
—
—
0
0
68
705
0.96
0.08
1.6
1.5
—
—
—
0
0
224
2201
1.02
0.08
7.2
8.7
23.70
24.15
mmol/l
1.36
217
2097
6
57
1.05
0.08
1.2
1.3
—
—
—
0
0
5
61
0.82
0.08
1.0
1.1
1115.40
1445.26
miu/ml
—
5
61
119
1161
1.03
0.08
1.7
2.3
0.01
0.05
g/l
1.53
104
1034
7
64
1.09
0.08
1.0
1.1
—
—
—
0
0
19
205
0.93
0.08
2.2
2.4
—
—
—
0
0
7
68
1.03
0.07
1.0
1.1
—
—
—
0
0
7
68
1.03
0.07
1.0
1.1
—
—
—
0
0
8
75
1.07
0.07
1.1
1.3
—
—
—
0
0
45
469
0.96
0.07
1.7
2.0
14.63
27.17
mg/l
—
8
101
8
77
1.04
0.07
1.1
1.2
—
—
—
0
0
30
284
1.06
0.07
1.2
1.2
5.38
5.03
u/ml
0.06
13
129
18
194
0.93
0.07
1.1
1.2
—
—
—
0
0
7
81
0.86
0.07
1.0
1.4
1.42
1.43
g/l
—
7
81
7
81
0.86
0.07
1.4
1.5
—
—
—
0
0
7
84
0.83
0.07
1.4
1.6
—
—
—
0
0
477
4726
1.01
0.07
5.2
6.9
4.92
5.03
kpa
1.42
450
4476
9
87
1.03
0.07
1.1
1.1
—
—
—
0
0
57
551
1.04
0.06
1.3
1.4
—
—
—
0
0
8
91
0.88
0.06
1.4
1.8
40.95
19.16
ug/l
—
8
85
8
93
0.86
0.06
2.8
2.4
—
—
—
0
0
12
109
1.10
0.06
1.2
1.2
139.50
273.32
iu/ml
1.34
12
109
221
2181
1.01
0.06
2.6
2.3
368.61
372.91
nmol/l
0.10
209
1987
15
139
1.08
0.05
1.1
1.2
—
—
—
0
0
476
4725
1.01
0.05
5.2
6.9
11.49
11.60
kpa
0.21
449
4469
94
959
0.98
0.05
3.3
3.4
4.34
4.25
pmol/l
0.36
87
818
256
2586
0.99
0.05
4.4
7.0
23.88
24.30
mmol/l
0.80
238
2466
19
179
1.06
0.05
2.6
2.7
31.40
33.69
%
—
10
109
18
191
0.94
0.04
1.6
2.1
16.56
17.74
%
0.19
18
184
767
7703
0.99
0.04
1.8
1.8
1103.77
1140.86
nmol/l
0.54
588
5740
378
3805
0.99
0.04
6.0
7.8
114.95
121.16
g/l
7.06
365
3705
107
1055
1.01
0.03
1.5
2.4
0.00
0.00
g/l
-0.00
92
947
60
611
0.98
0.02
1.3
1.5
54265.63
72697.67
e6/l
0.31
35
365
104
1031
1.01
0.01
1.3
1.5
—
—
—
0
0
18
187
0.96
0.01
1.6
2.1
—
—
—
0
0
14
134
1.04
0.00
1.1
1.0
—
—
—
0
0
66
666
0.99
0.00
1.4
1.5
1270.17
1714.64
e6/l
0.77
48
470
68
686
0.99
0.00
3.8
1.3
58.23
44.01
u/l
0.41
61
594
11
115
0.96
0.00
1.1
1.1
—
—
—
0
0
24
245
0.98
0.00
1.2
1.2
7.41
7.85
mmol/l
0.35
19
203
38
375
1.01
0.00
1.1
1.2
312.00
293.81
u/ml
0.17
25
227
111
1115
1.00
0.00
1.5
1.7
—
—
—
0
0
12
119
1.01
0.00
1.1
1.1
—
—
—
0
0
22
219
1.00
0.00
1.1
1.2
—
—
—
0
0
42
421
1.00
0.00
1.1
1.2
—
—
—
0
0
108
1079
1.00
0.00
1.5
2.4
0.00
0.00
g/l
1.04
93
953
149
1489
1.00
0.00
1.6
2.3
9.84
10.48
g/l
1.29
127
1290
228
2281
1.00
0.00
3.2
4.5
108.67
110.85
ng/l
0.11
201
1960
5
52
0.96
0.00
2.0
2.1
—
—
—
0
0
0
7
0.00
0.00
0.0
2.7
—
—
—
0
0
0
7
0.00
0.00
0.0
1.7
—
2.20
—
0
7
5
52
0.96
0.00
2.0
2.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
11
110
1.00
-0.00
6.4
8.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
3.0
—
2.78
—
0
6
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
6
67
0.90
-0.00
1.0
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
6.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
1.28
—
0
5
9
90
1.00
-0.00
2.4
2.1
37.11
32.41
%
—
9
83
0
8
0.00
-0.00
0.0
1.0
—
1465.88
—
0
8
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
5
55
0.91
-0.00
1.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
8.22
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
7
70
1.00
-0.00
3.6
1.4
295.00
226.83
%
—
7
65
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
3.8
—
32.50
—
0
6
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
4.9
—
350.22
—
0
9
6
64
0.94
-0.00
1.2
1.1
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: RX_L02BB – L02BB Anti-androgens
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).